Rejection of a Nonimmunogenic Melanoma by Vaccination with Natural Melanoma Peptides on Engineered Antigen-Presenting Cells

Matteo Bellone, Giandomenica Iezzi, Alfonso Martin-Fontecha, Loredana Rivolta, Angelo A. Manfredi, Maria Pia Protti, Massimo Freschi, Paolo Dellabona, Giulia Casorati, Claudio Rugarli

Research output: Contribution to journalArticle

Abstract

Naturally processed peptides, obtained by acid extraction of tumor cells, contain Ags able to activate specific CTL in vitro. We recently reported that the nonprofessional APC, RMA-S, expressing the B7.1 molecule (RMA-S/B7), pulsed with naturally processed peptides from the nonimmunogenic B16F1 melanoma (B16F1a.e.) primed syngenic CD8+ T cells against the tumor in vitro. Here, we show the rejection of B16F1 melanoma by C57BL/6 mice after immunization with RMA-S/B7 cells pulsed with B16F1a.e. This response is critically dependent on both CD4+ and CD8+ cells, but not on NK cells. However, only CD8+ T cells exert anti-B16F1 cytolitic activity in vitro. Moreover, RMA-S/B7 cells pulsed with B16F1a.e. can be used to prevent the growth of 24-h preestablished melanomas. These results may have important implications for the clinical use of natural peptide fractions of tumor cells as therapeutic cancer vaccines.

Original languageEnglish
Pages (from-to)783-789
Number of pages7
JournalJournal of Immunology
Volume158
Issue number2
Publication statusPublished - Jan 15 1997

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Rejection of a Nonimmunogenic Melanoma by Vaccination with Natural Melanoma Peptides on Engineered Antigen-Presenting Cells'. Together they form a unique fingerprint.

  • Cite this